BioSpace News Archive

Liminal BioSciences Inc. (Nasdaq: LMNL) (“Liminal BioSciences” or the “Company”), today reported its financial results for the third quarter ended September 30, 2021.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent developments.

Innovative medical device manufacturer Anatomics Pty Ltd announces the world first use of revolutionary StarPore polymer tissue scaffold for thoracic reconstructive surgery in Australia, USA, UK, Singapore, Portugal and New Zealand.

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced financial results for the third quarter ended September 30, 2021.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today reported financial results for the quarter ended September 30, 2021, and provided a corporate update.

Ascletis Pharma Inc. (HKEX: 1672) announces today that Phase IIa and IIb clinical studies of PD-L1 antibody ASC22 (Envafolimab) for Hepatitis B Virus (HBV) functional cure have been selected for inclusion in the “Best of The Liver Meeting’s summary slide deck in the Viral Hepatitis category” at The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD).

Renovacor, Inc., a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and related diseases, announced financial results for the third quarter of 2021 and provided a corporate update.

Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced today that the U.S. Food and Drug Administration (FDA) has given 501(k) marketing clearance to its Circular External Fixation System.

Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Alan Fuhrman, Interim CEO and President, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Amarin Corporation plc announced that data adding to the growing body of knowledge on VASCEPA®/VAZKEPA in patients with prior peripheral artery disease at risk for major adverse cardiovascular events were delivered in a Rapid Fire Oral Session Presentation at the American Heart Association Scientific Sessions 2021, which took place virtually from November 13-15, 2021.